GET DAILY SIGNALSCadrenal Therapeutics (CVKD): Analyst Targets Point to +1,300% Upside from Current Levels
Key Takeaways
- The central $14 stock price target is the arithmetic mean of three current analyst price targets, which span roughly $12 to $17; the most clearly identified is a $13 target from H.C. Wainwright.
- With shares trading near $1.00, reaching $14 would require a very large move of more than 1,200%, far beyond the 10% minimum needed for a meaningful objective.
- The wide $12–$17 analyst range and the very small number of covering analysts mean the average carries unusually low statistical confidence.
- The strongest supporting factor is clinical progress on lead candidate CAD-1005, including a completed End-of-Phase 2 meeting with the FDA aimed at a Phase 3 path.
- The biggest risks are a pre-revenue balance sheet, ongoing dilution, potential Nasdaq listing pressure, and binary clinical-trial outcomes.
- Readers can explore additional pages for Major News, Today's Price Move, Forecast, and Earnings on this company.
- For broader market signals and automation, explore Trending AI Robots.
Analyst Price Targets and Consensus View
Cadrenal Therapeutics, Inc. (CVKD) is a late-stage biopharmaceutical company developing therapies for cardiovascular and thrombotic conditions. Coverage remains thin, with data aggregators drawing on S&P Global reporting roughly three current analyst price targets in the $12 to $17 range. This produces an average of about $14 and carries a "Strong Buy" tilt overall. The single most clearly identified figure is a $13 target from H.C. Wainwright, issued by analyst Joseph Pantginis and revised downward from $32 in early April 2026 to reflect an updated share count, financing needs, and the incorporation of CAD-1005 into the model.
Because only a handful of analysts cover the name, the $14 mean functions best as a rough benchmark rather than a statistically robust consensus. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Several aggregators still show older targets well above $20, but those appear stale and have not been updated to reflect the current share price. Analyst reasoning focuses almost entirely on the clinical and regulatory path for CAD-1005.
Current Market Position and Path Toward the Target
Shares trade near $1.00, placing the stock at the low end of a 52-week range of roughly $1.76 to $14.64. Reaching the $14 central target would imply upside of roughly 1,300%, an exceptionally large move. Such a repricing would likely require successful advancement of the lead program into late-stage development along with meaningful non-dilutive funding. The company is pre-revenue, so any progress toward the target would be event-driven rather than the result of steady fundamental improvement.
What Could Support a Move Toward the Target
The primary catalyst remains clinical. Cadrenal completed an End-of-Phase 2 meeting with the FDA to align on a Phase 3 registrational path for CAD-1005, an anticoagulant candidate. Positive regulatory clarity, a well-designed Phase 3 trial, and subsequent positive data would represent the clearest drivers of a re-rating. Additional support could come from stabilization of the capital structure, reduced financing overhang, and renewed institutional interest in a name tied to an unmet medical need in thrombotic and cardiovascular conditions.
What Could Prevent the Target From Being Reached
The obstacles are substantial. The company generates no product revenue and relies on equity raises to fund development, a pattern that has diluted shareholders and driven the price sharply lower. A Nasdaq minimum-bid-price deficiency or further reverse-stock-split activity could keep the share price depressed. Clinical development is inherently binary, and a Phase 3 delay, safety signal, or failure would materially undermine the investment thesis. The $14 mean could quickly become irrelevant if the capital structure changes again.
Technical Levels and Market Structure
With the stock trading near multi-year lows, meaningful technical reference points are limited. The prior 52-week low area near $1.76 sits above the current price and would act as overhead resistance on any recovery, followed by psychological whole-dollar levels. The prolonged downtrend and wide spread between the current price and the analyst range mean conventional support and resistance zones offer little guidance for a move of this magnitude.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though individual assumptions can differ and the H.C. Wainwright target has already been revised sharply downward once this year. Key items to watch include updates on the Phase 3 design and initiation for CAD-1005, the next quarterly earnings and accompanying cash-runway commentary, any new financing or reverse-split announcements, FDA interactions, and analyst target revisions.
Using AI Tools for Ongoing Monitoring
In my view, tools that apply artificial intelligence to market data can help surface shifts in trend for a low-priced, high-volatility name like this. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. From what I see, such resources complement traditional analysis without replacing careful review of clinical and financial developments.
Exploring AI Daily Buy/Sell Signals
Tickeron’s AI Daily Buy/Sell Signals apply artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a low-priced, high-volatility name like CVKD, such tools can help traders surface opportunities, monitor open positions, and spot shifts in trend more efficiently than manual scanning. Traders interested in automating this process can explore the signals as part of a broader, data-informed routine.
Promo Section
I have found Tickeron’s AI Daily Buy/Sell Signals useful for tracking names like this one alongside my own review of clinical updates and financing activity. The platform applies AI across a wide universe of stocks to flag potential shifts, which helps me stay organized when coverage is thin and volatility is high. It serves as one more data point in an overall research process rather than a standalone decision tool.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
CVKD sees its Stochastic Oscillator ascends from oversold territory
On October 29, 2026, the Stochastic Oscillator for CVKD moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 46 instances where the indicator left the oversold zone. In 39 of the 46 cases the stock moved higher in the following days. This puts the odds of a move higher at over 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CVKD's RSI Indicator exited the oversold zone, 24 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
Following a +4.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where CVKD advanced for three days, in 146 of 181 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 27, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CVKD as a result. In 59 of 64 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVKD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for CVKD entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.859) is normal, around the industry mean (3.154). P/E Ratio (-0.202) is within average values for comparable stocks, (-1.071). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.299) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. CVKD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVKD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement